BEIJING, Aug. 23, 2021 /PRNewswire/ -- Concord Medical
Services Holdings Limited ("Concord Medical" or the "Company")
(NYSE: CCM), a healthcare provider specializes in cancer treatment,
research, education, and prevention by establishing proton centers
and specialty cancer hospitals and operating an extensive network
of radiotherapy and diagnostic imaging centers in China, today
announced an investment of RMB400.0
million (US$62.2 million) in
Concord Medical's subsidiary, Meizhong Jiahe Medical Science &
Technology Development Group Co., Ltd. ("Meizhong Jiahe") from
several investors led by WisdoMont Asset Management (Shanghai) Co., Ltd. ("WisdoMont Capital"), a
renowned investment institution and one of the existing
shareholders of Meizhong Jiahe.
As the most important operating platform of Concord Medical,
Meizhong Jiahe focuses on the development and management of
comprehensive cancer hospitals and standalone radiotherapy and
diagnostic imaging centers in China. Meizhong Jiahe is committed to provide
its patients with high-quality patient-centered multidisciplinary
cancer care services. In addition, Meizhong Jiahe provides the
cutting-edge proton therapy treatment option in the Company's
Beijing, Shanghai and Guangzhou cancer hospitals. Meizhong Jiahe is
dedicated to become a premier cancer medical services provider for
the patients in China by helping
to treat the cancer diseases by offering international recognized
clinical research, multidisciplinary treatment care approach and
advanced hospital management systems.
"Concord Medical has rapidly developed a leadership position in
the large and fast-growing market in China for cancer treatment," said Mr. Yue Yu,
Chief Executive Officer and Co-founder of WisdoMont Capital. "What
the team of Concord Medical has developed in the recent years is
truly impressive, and we are excited to have an opportunity working
with its highly specialized management team to create a leader in
the market. Concord Medical is a great example of the type of
founder-led, capital-efficient business that we would like to
invest in."
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare
provider specialized in cancer treatment, research, education and
prevention. The Company operates a network of medically advanced
comprehensive cancer hospitals and standalone radiotherapy and
diagnostic imaging centres in China. The Company focuses on providing
multidisciplinary cancer care approach in all areas of oncology
services in its cancer hospitals. The Company also equips its
hospitals with technologically advanced equipment such as the
state-of-the-art proton therapy system in its premium cancer
hospitals in top-tier cities such as Shanghai and Guangzhou. In addition, the Company saw the
opportunity of the expanding market of medical equipment in
China and developed its product
life-cycle management services form its existing medical equipment
and consumable sales services. As of December 31, 2020, the
Company operated a network of 27 radiotherapy centers and
diagnostic imaging centers, which are based in 20 hospitals,
established under long-term lease and management services
arrangements with the Company and spanning over 20 cities across 13
provinces and administrative regions in China. To ensure the
commitment to the highest standard of medical services for
patients, the Company offers ongoing education and training for
doctors and other medical professionals in its network hospitals
and centres in both domestic and overseas medical institutions. For
more information, please see http://ir.ccm.cn.
Safe Harbor Statement
This announcement contains forward-looking statements. These
forward-looking statements can be identified by words or phrases
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar expressions.
Forward-looking statements are inherently subject to uncertainties
and contingencies beyond the Company's control and based upon
premises with respect to future business decisions, which are
subject to change. A number of important factors could cause actual
results to differ materially from those contained in any
forward-looking statement. The Company does not undertake any
obligation to update any forward-looking statement, except as
required under applicable laws.
View original
content:https://www.prnewswire.com/news-releases/concord-medical-completes-rmb-400-million-funding-round-led-by-consortium-investors-301360451.html
SOURCE Concord Medical Services Holdings Limited